Direkt zum Inhalt
Merck
  • Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.

Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.

Rheumatology (Oxford, England) (2014-12-21)
Isidoro González-Álvaro, Carmen Martínez-Fernández, Benito Dorantes-Calderón, Rosario García-Vicuña, Blanca Hernández-Cruz, Alicia Herrero-Ambrosio, Olatz Ibarra-Barrueta, Emilio Martín-Mola, Emilio Monte-Boquet, Alberto Morell-Baladrón, Raimon Sanmartí, Jesús Sanz-Sanz, Francisco Javier de Toro-Santos, Paloma Vela, José Andrés Román Ivorra, José Luis Poveda-Andrés, Santiago Muñoz-Fernández
ZUSAMMENFASSUNG

The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA. Recommendations were established via consensus by a panel of experts in rheumatology and hospital pharmacy, based on analysis of available scientific evidence obtained from four systematic reviews and on the clinical experience of panellists. The Delphi method was used to evaluate these recommendations, both between panellists and among a wider group of rheumatologists. Previous concepts concerning better management of RA, AS and PsA were reviewed and, more specifically, guidelines for the optimization of biologic therapies used to treat these diseases were formulated. Recommendations were made with the aim of establishing a plan for when and how to taper biologic treatment in patients with these diseases. The recommendations established herein aim not only to provide advice on how to improve the risk:benefit ratio and efficiency of such treatments, but also to reduce variability in daily clinical practice in the use of biologic therapies for rheumatic diseases.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Borandimethylsulfid-Komplex
Sigma-Aldrich
Borandimethylsulfid-Komplex -Lösung, 2.0 M in THF
Sigma-Aldrich
Borandimethylsulfid-Komplex -Lösung, 1.0 M in 2-methyltetrahydrofuran